Article
March 17, 2025
Author(s):
Fact checked by:
Conference|SGO Annual Meeting
Maintenance selinexor improved progression-free survival in TP53 wild-type advanced endometrial cancer.
Newsletter
Stay up to date on the most recent and practice-changing oncology data
Subscribe Now!
Related Videos
Dr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer SubgroupsDr Silverstein on the Efficacy of Abemaciclib Plus Hormonal Therapy in Recurrent Low- or High-Grade Serous Ovarian CancerDr Grisham on the Efficacy of Avutometinib Plus Defactinib in Gynecologic Mesonephric CancerDr Van Gorp on the Long-Term Efficacy of Mirvetuximab Soravtansine in FRĪ±+ Platinum-Resistant Ovarian CancerDr Wagar on the Evolution of Advanced/Recurrent Endometrial Cancer ManagementDr Salani on Novel Trial Designs and Therapies in Gynecologic MalignanciesDr Richardson on the Role of Triplet Regimens in Newly Diagnosed MyelomaDr Kalinsky on the Potential to Switch CDK4/6 Inhibitors in HR+ Metastatic Breast CancerDr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast CancerDr Jagsi on Factors for RT Omission After Breast-Conserving Surgery in Early Breast Cancer